Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of UCB7853 in Healthy Volunteers and Parkinson's Disease
NCT04651153Phase 1Completed
- Sponsor
- UCB
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing UCB7853 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-emergent Adverse Events in healthy male participants and Incidence of Treatment-emergent Adverse Events in participants with Parkinson's Disease. Started Dec 2020; status: completed.
02
Drugs
UCB7853
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04651153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651153.